The Conversation (0)
BioVie received clearance from the US Patent and Trademark Office regarding the company’s new drug candidate treating patients with advanced liver cirrhosis.
BioVie (OTCQB:BIVI) received clearance from the US Patent and Trademark Office regarding the company’s new drug candidate treating patients with advanced liver cirrhosis.
As quoted in the press release:
BioVie’s medical advisor Paolo Angeli, MD, and Company personnel pioneered this potential new therapeutic approach. The patent is supported by clinical data generated by Dr. Angeli and licensed exclusively to the Company by the University of Padova, Italy. It is assigned to BioVie and will provide patent exclusivity in the US under the issued claims through 2036.
“Dr. Angeli is deeply committed to improving medical therapy for these desperately ill patients and it has been our privilege to work with him,” commented Jonathan Adams, BioVie CEO. “This newly-issued patent provides strong intellectual property protection for our lead therapeutic candidate BIV201. It positions BioVie as the emerging leader in developing a new drug therapy for ascites and potentially other deadly complications of advanced liver cirrhosis.” BIV201 could become the first drug ever approved by the FDA for treating refractory ascites due to liver cirrhosis, a life-threatening condition which affects about 10,000 Americans.
Click here to read the full press release.
Source: www.marketwired.com
